Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 141

  • The following term was not found in PubMed: Rous-Weil.
1.

Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma.

Morschhauser F, Fowler NH, Feugier P, Bouabdallah R, Tilly H, Palomba ML, Fruchart C, Libby EN, Casasnovas RO, Flinn IW, Haioun C, Maisonneuve H, Ysebaert L, Bartlett NL, Bouabdallah K, Brice P, Ribrag V, Daguindau N, Le Gouill S, Pica GM, Martin Garcia-Sancho A, López-Guillermo A, Larouche JF, Ando K, Gomes da Silva M, André M, Zachée P, Sehn LH, Tobinai K, Cartron G, Liu D, Wang J, Xerri L, Salles GA; RELEVANCE Trial Investigators.

N Engl J Med. 2018 Sep 6;379(10):934-947. doi: 10.1056/NEJMoa1805104.

PMID:
30184451
2.

Prescription Drug Coverage and Outcomes of Myeloma Therapy Among Medicare Beneficiaries.

Olszewski AJ, Dusetzina SB, Trivedi AN, Davidoff AJ.

J Clin Oncol. 2018 Oct 1;36(28):2879-2886. doi: 10.1200/JCO.2018.77.8894. Epub 2018 Aug 16.

PMID:
30113885
3.

A Novel Combination of the mTORC1 Inhibitor Everolimus and the Immunomodulatory Drug Lenalidomide Produces Durable Responses in Patients With Heavily Pretreated Relapsed Lymphoma.

Padrnos L, Ernst B, Dueck AC, Kosiorek HE, Ginos BF, Toro A, Johnston PB, Habermann TM, Leis JF, Mikhael JR, Nowakowski GS, Colgan J, Porrata L, Ansell SM, Witzig TE, Reeder C.

Clin Lymphoma Myeloma Leuk. 2018 Oct;18(10):664-672.e2. doi: 10.1016/j.clml.2018.06.013. Epub 2018 Jun 15.

PMID:
30104176
4.
5.

SOHO State-of-the-Art Update and Next Questions: MPN.

Bose P, Gotlib J, Harrison CN, Verstovsek S.

Clin Lymphoma Myeloma Leuk. 2018 Jan;18(1):1-12. doi: 10.1016/j.clml.2017.11.008. Review.

PMID:
29277359
6.

Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma.

Connors JM, Jurczak W, Straus DJ, Ansell SM, Kim WS, Gallamini A, Younes A, Alekseev S, Illés Á, Picardi M, Lech-Maranda E, Oki Y, Feldman T, Smolewski P, Savage KJ, Bartlett NL, Walewski J, Chen R, Ramchandren R, Zinzani PL, Cunningham D, Rosta A, Josephson NC, Song E, Sachs J, Liu R, Jolin HA, Huebner D, Radford J; ECHELON-1 Study Group.

N Engl J Med. 2018 Jan 25;378(4):331-344. doi: 10.1056/NEJMoa1708984. Epub 2017 Dec 10. Erratum in: N Engl J Med. 2018 Mar 1;378(9):878.

7.

Volume-Outcome Relationship in Surgical Interventions for Spinal Metastases.

Schoenfeld AJ, Ferrone ML, Sturgeon DJ, Harris MB.

J Bone Joint Surg Am. 2017 Oct 18;99(20):1753-1759. doi: 10.2106/JBJS.17.00368.

PMID:
29040130
8.

Surgical Roles for Spinal Involvement of Hematological Malignancies.

Kim SI, Kim YH, Ha KY, Lee JW, Lee JW.

J Korean Neurosurg Soc. 2017 Sep;60(5):534-539. doi: 10.3340/jkns.2016.1011.001. Epub 2017 Aug 30.

9.

Subsidies for Oral Chemotherapy and Use of Immunomodulatory Drugs Among Medicare Beneficiaries With Myeloma.

Olszewski AJ, Dusetzina SB, Eaton CB, Davidoff AJ, Trivedi AN.

J Clin Oncol. 2017 Oct 10;35(29):3306-3314. doi: 10.1200/JCO.2017.72.2447. Epub 2017 May 25.

10.

Risk and impact of tuberculosis in patients with multiple myeloma.

Tsai CK, Huon LK, Ou SM, Kuan AS, Yeh CM, Lee YT, Liu YC, Chen TJ, Liu JH, Liu CJ.

Leuk Lymphoma. 2017 Nov;58(11):2598-2606. doi: 10.1080/10428194.2017.1312369. Epub 2017 May 9.

PMID:
28482714
11.

Replication Study: BET bromodomain inhibition as a therapeutic strategy to target c-Myc.

Aird F, Kandela I, Mantis C; Reproducibility Project: Cancer Biology.

Elife. 2017 Jan 19;6. pii: e21253. doi: 10.7554/eLife.21253. Erratum in: Elife. 2018 Jan 08;7:.

12.

Risk of Hodgkin lymphoma according to immigration status and origin: a migrant cohort study of 2.3 million Jewish Israelis.

Levine H, Leiba M, Bar Zeev Y, Keinan-Boker L, Derazne E, Leiba A, Kark JD.

Leuk Lymphoma. 2017 Apr;58(4):959-968. doi: 10.1080/10428194.2016.1220552. Epub 2016 Aug 26.

PMID:
27561882
13.

Zoledronic Acid may reduce intraoperative bleeding in spinal tumors: a prospective cohort study.

Wu J, Zheng W, Tan Y, Hu XY, Huang Q, Fan KH, Ma J, Xiao WJ, Ren JD, Hou J, Xiao JR.

Biomed Res Int. 2015;2015:936307. doi: 10.1155/2015/936307. Epub 2015 Jan 22.

14.

Treatment of Non-transplant patients with multiple myeloma: routine treatment by office-based haematologists in Germany--data from the prospective Tumour Registry Lymphatic Neoplasms (TLN).

Knauf W, Abenhardt W, Aldaoud A, Nusch A, Grugel R, Münz M, Hartmann H, Marschner N; TLN Study Group.

Oncol Res Treat. 2014;37(11):635-6, 638-44. doi: 10.1159/000368315. Epub 2014 Oct 17.

15.

Prognostic parameters and spinal metastases: a research study.

Daniel JW, Veiga JC.

PLoS One. 2014 Oct 13;9(10):e109579. doi: 10.1371/journal.pone.0109579. eCollection 2014.

16.

Characteristics and outcomes of patients with multiple myeloma who develop therapy-related myelodysplastic syndrome, chronic myelomonocytic leukemia, or acute myeloid leukemia.

Pemmaraju N, Shah D, Kantarjian H, Orlowski RZ, Nogueras González GM, Baladandayuthapani V, Jain N, Wagner V, Garcia-Manero G, Shah J, Ravandi F, Pierce S, Takahashi K, Daver N, Nazha A, Verstovsek S, Jabbour E, De Lima M, Champlin R, Cortes J, Qazilbash MH.

Clin Lymphoma Myeloma Leuk. 2015 Feb;15(2):110-4. doi: 10.1016/j.clml.2014.07.001. Epub 2014 Jul 15.

17.

A phase 1/2 study of oral panobinostat combined with melphalan for patients with relapsed or refractory multiple myeloma.

Berenson JR, Hilger JD, Yellin O, Boccia RV, Matous J, Dressler K, Ghazal HH, Jamshed S, Kingsley EC, Harb WA, Noga SJ, Nassir Y, Swift RA, Vescio R.

Ann Hematol. 2014 Jan;93(1):89-98. doi: 10.1007/s00277-013-1910-2. Epub 2013 Oct 18.

PMID:
24135804
18.

A randomized phase II trial of fludarabine/melphalan 100 versus fludarabine/melphalan 140 followed by allogeneic hematopoietic stem cell transplantation for patients with multiple myeloma.

Bashir Q, Khan H, Thall PF, Liu P, Shah N, Kebriaei P, Parmar S, Oran B, Ciurea S, Nieto Y, Jones R, Hosing CM, Popat UR, Dinh YT, Rondon G, Orlowski RZ, Shah JJ, De Lima M, Shpall E, Champlin R, Giralt S, Qazilbash MH.

Biol Blood Marrow Transplant. 2013 Oct;19(10):1453-8. doi: 10.1016/j.bbmt.2013.07.008. Epub 2013 Jul 17.

19.

Expectations of serious adverse events at the end of life of patients with acute myeloid leukemia who receive salvage therapy.

Cardenas-Turanzas M, Ravandi-Kashani F, Cortes JE, Jabbour E, Faderl S, Pierce SA, Kantarjian H.

Clin Lymphoma Myeloma Leuk. 2013 Oct;13(5):579-83. doi: 10.1016/j.clml.2013.03.021. Epub 2013 Jun 10.

20.

[Clinical research of reduced-intensity allogeneic hematopoietic stem cell transplantation for multiple myeloma].

Guo Z, Chen HR, Liu XD, Lou JX, Yang K, Zhang Y, Chen P, Wang SY, He XP.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2013 Apr;21(2):441-5. doi: 10.7534/j.issn.1009-2137.2013.02.038. Chinese.

PMID:
23628050

Supplemental Content

Loading ...
Support Center